Demographic Data
Up to May 2018, a total of 4,571 courses of biologics were used in 2,790 patients (1,608 women and 1,182 men) with various rheumatic diseases, according to our Registry. The mean age at the commencement of treatment was 47 years (range 1-89 years). More than half of the patients suffered from rheumatoid arthritis, while the others were mainly patients with ankylosing spondylitis and psoriatic arthritis. Other indications of biologics are shown in Table  1 . The longest duration of therapy was 174 months. 
Infection Requiring Hospitalization
There were 156 episodes of infective complications requiring hospitalization. More than half of them (i.e., 86 cases) occurred during the first 12 months of biological therapy.
Tuberculosis
A total of 64 cases of TB were reported: 31 related to Infliximab, 12 related to Etanercept, 10 related to Adalimumab, 6 related to Golimumab, 3 related to Tocilizumab and 2 related to Tofacitinib. Nearly 40% of the cases (i.e., 24 cases) occurred in the first 6 months of treatment. There were 522 abnormal CXRs before treatment and isoniazid chemoprophylaxis was given to 924 patients with latent TB as defined by either positive MT2 (≥ 10mm induration) or positive in IGRA test. 
